Less may be more: smaller lung surgery tested against standard removal
NCT ID NCT07169903
First seen Jun 26, 2026 ยท Last updated Jun 26, 2026
Summary
This study compares two types of surgery for people with a specific kind of lung cancer (adenocarcinoma) that is 2-3 cm in size and has a low-to-intermediate grade. One surgery removes just the part of the lung with the tumor (segmentectomy), while the other removes an entire lobe (lobectomy). The goal is to see if the smaller surgery works just as well at preventing the cancer from coming back, while possibly helping patients keep more lung function. About 587 participants will be followed for 5 years after surgery.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- surgery (segmentectomy or lobectomy)
- What this could lead to
- If successful, this could show that a less extensive surgery (segmentectomy) is as effective as a larger one (lobectomy) for certain lung cancers, potentially preserving more lung function and improving recovery.
- What could go wrong
- This is a Phase 3 trial, but results are years away. The benefit may be small or not apply to all patients. Surgery always carries risks like infection or complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI be a Pathologist's second opinion?
- Blood tests could unlock early clues for three major lung diseases
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
- Why some Never-Smokers get lung cancer: a new study investigates
- Could an asthma drug help fight lung cancer? early trial investigates
- Vaccine trains immune system to hunt down cancer cells